Publications by authors named "P C Philips"
Background And Methods: The incidence of pancreatic cancer is increasing, and up to 55% of patients present with metastatic disease at the time of diagnosis. Many patients also develop metastatic disease following surgical resection. The impact of metastatic patterns on outcomes has not been described.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how to better manage exocrine pancreatic insufficiency (EPI) in pancreatic adenocarcinoma patients through treatments like oral pancreatic enzyme replacement therapy (PERT) and immobilized lipase cartridges (RELiZORB) during a specific time frame at Louisville Medical Center.
- EPI symptoms were prevalent in 80% of the 35 patients studied, with many using jejunostomy tubes and enzyme cartridges; those without tubes relied on PERT, both approaches significantly improved patient quality of life.
- The findings emphasize the importance of early EPI management to enhance patient care, facilitate a return to cancer treatment post-surgery, and improve overall quality of life for those undergoing pancreatic
Background: The University of Louisville has observed a near 70% drop in resectable/borderline resectable metastatic colorectal cancer in the past 5 years. The aim of this study was to evaluate the distribution of colon cancer metastasis at diagnosis and at recurrence.
Patients And Methods: Stage was defined by the American joint committee on cancer (AJCC) eighth edition.
Objective: In this pilot study, we sought to determine if preoperative circulating tumor DNA could be a useful predictor to avoid futile metastasectomy, predict early postoperative recurrence, and determine optimal chemotherapy duration during the management of patients with resectable metastatic colorectal cancer.
Methods: Patients from 2021 to 2023 were enrolled prospectively and evaluated with circulating tumor DNA preoperatively and postoperatively for detection of recurrence. Clinicopathologic and treatment factors as well as disease-free survival were compared between those with undetectable versus detectable preoperative circulating tumor DNA.